Vaxess Technologies, Inc.

9 articles about Vaxess Technologies, Inc.

• Vaxess Announces Production of The First GMP Batch of MIMIX™ Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial

  4/5/2022

  Vaxess Technologies announced significant progress towards clinical entry for the company’s lead program, MIMIX-Flu.

• Vaxess Bolsters Commitment To Vaccine Patch Leadership With Purpose-Built Cambridge Lab And Fortified Management Team With The Addition Of A Veteran CFO And Head Of Device Development

  3/1/2022

  Vaxess Technologies, Inc., an innovative life sciences company developing a pipeline of shelf-stable and simple-to-apply vaccines on the MIMIX patch platform announced occupancy of a second new facility and significant additions to the leadership team.

• Vaxess Technologies Awarded NIH Grant of up to $2.85 Million to Drive MIMIX™ Sustained Release Vaccine Patch Into a 2022 Phase 1 Human Trial

  4/22/2021

  Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH).

• Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch

  1/22/2021

  Vaxess Technologies, Inc., an innovative biotechnology company developing the MIMIX™ smart release patch, was awarded a grant from the National Science Foundation (NSF award number 2030305) and a subcontract from the Defense Advanced Research Projects Agency

• Vaxess Technologies to Develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen

  9/14/2020

  Vaxess Technologies, an innovative biotechnology company developing the MIMIX smart release patch, has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC) (TPEx: 6547.TWO), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system.

• Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch

  10/16/2019

  Vaxess will have exclusive rights to commercialize the MIMIX Flu Smart Release Patch in the US and Europe, while GC Pharma obtains rights for the South Korean market

• 

  Vaxess Technologies Closes Funding for Administering Vaccines Through a Bandage

  7/2/2019

  Cambridge, Mass.-based Vaxess Technologies is inching closer to developing a bandage-like product that will be able to administer vaccines and other therapeutics through the skin.

• Vaxess Technologies Closes Final Tranche of $8.2 Million Series A and Appoints Dr. Purnanand Sarma to the Board

  6/27/2019

  Vaxess Technologies, a biotechnology company redefining drug delivery with the silk-powered MIMIX smart release patch, announced it has closed the final tranche of an $8.2 million Series A round.

• Vaxess Technologies, Inc. Receives Grants Totaling $6 Million To Develop Microneedle Vaccines For Polio, Measles, Rubella

  3/6/2017